
    
      Study D6770C00001 is a Phase 1, first-in-human, multicenter, open-label, dose-escalation
      study to evaluate the safety, tolerability, antitumor activity, pharmacokinetics, and
      immunogenicity of IPH5201 in adult subjects with advanced solid tumors, when administered as
      monotherapy or in combination with durvalumab Â± oleclumab.
    
  